Key Stats for Fresenius SE Stock
- 1-Year Price Change for $FRE Stock: 51.0%
- Current Share Price: $55.09
- 52-Week High: $58.69
- $FRE Stock Price Target: $61.18
Fresenius SE: Can the German Healthcare Group Continue Building Momentum Into 2027?
Fresenius SE (FRE), one of Germany’s leading healthcare groups, has delivered a strong operational performance in 2025 as it executes its new corporate strategy following the deconsolidation of Fresenius Medical Care (FMC). In Q1 2025, the company’s revenue (excluding FMC) stood at €5.63 billion, representing 7% organic growth compared to Q1 2024. Adjusted EBIT grew to €654 million, an increase of 4% in constant currency from a year earlier, driven by the strong operating performance of Fresenius Kabi. This momentum led the company to raise its full-year EBIT growth guidance to 4-8% in Q3 2025.
Despite continued market volatility, analysts remain optimistic, with a 12-month price target averaging around €52.90 per share, compared to the current price in the €47–€48 range. This suggests an upside potential of approximately 10–11%, contingent upon Fresenius continuing to deliver on its operational efficiency goals and maintaining strong growth in its key divisions.
Looking ahead, Fresenius’ growth will depend on sustaining strong performance and maintaining its leadership in healthcare services. The company is pushing forward with innovations in its dialysis and hospital segments (Helios), where it aims to improve patient outcomes and expand in emerging markets.
Additionally, Fresenius has invested heavily in its digital healthcare offerings and its Biopharma segment, which are key drivers of future revenue growth. However, pressure on its margins from labor and material costs, as well as regulatory risks in key regions like the U.S., remain potential headwinds.
Value stocks like Fresenius in under 60 seconds (Free with TIKR)
Inside Market Sentiment on Fresenius SE
Investor sentiment on Fresenius SE is constructively positive. While the company is grappling with market normalization (like the loss of prior-year energy relief funds in its German hospital segment), its solid foundation in the global healthcare market and focus on growth in emerging economies offer strong long-term potential. Analysts are particularly focused on Fresenius’ ability to drive margins higher, especially in its core businesses Fresenius Kabi (Pharma/MedTech) and Fresenius Helios (Hospitals), and expand its digital health solutions.
Risks include ongoing pricing pressures in key markets, especially in the U.S. healthcare system, as well as potential regulatory changes. Nevertheless, Fresenius’ broad international presence and strong portfolio of healthcare services continue to make it a valuable option for long-term investors looking for stability in the healthcare sector. If the company can execute its growth strategies and continue to improve profitability (as demonstrated by its raised full-year EBIT guidance of 4%–8%), it will remain a key player to watch through 2025.
What Will Fresenius SE’s Stock Price Be in 3 Years? Build Your Model in 30 Seconds
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
